Skip to content

Cardiac and Pulmonary Assessment in Egyptian Patients With Rheumatoid Arthritis

Cardiac and Pulmonary Assessment in Egyptian Patients With Rheumatoid Arthritis and Their Correlation With Disease Activity

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05938244
Enrollment
34
Registered
2023-07-10
Start date
2023-08-31
Completion date
2024-06-30
Last updated
2023-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

cardiac pulmonary rheumatoid arthritis

Brief summary

To determine cardiac and pulmonary involvement in RA patients To assess the correlation between cardiopulmonary findings in RA patients with disease activity. To compare between diaphragmatic ultrasonography and PFT i.e. spirometry as a screening tool for restrictive pulmonary disorders. To assess correlation between anterior chest wall ultrasound and pulmonary function test in RA patients.

Detailed description

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease with systemic manifestations targeting primarily synovial joints and periarticular tissues, with a 1-3% prevalence, it is the most prevalent form of inflammatory arthritis.(1,2) Although synovitis is the pathological hallmark of RA, numerous extra-articular symptoms and comorbidities are probably present.(3) Cardiovascular and pulmonary system diseases are the two main causes of death in RA patients, and their symptoms are the most serious.(2,3) Patients with RA have a 50% greater risk of CV mortality and a two-fold increased risk of myocardial infarction, which is the most common cause of death in this population. (4) Echocardiographic examination is considered a good predictive tool for some cardiac conditions with early findings while no clinical signs is yet found on these patients. (5) The second major cause of death in patients with RA is respiratory disease, which occurs in 30-40% of patients.(6) Sometimes the disease is silent until it has lung complications, which come before joint problems. RA may affect the lung interstitium, airways, and pleurae, while pulmonary vascular involvement is less frequent.(7) Diaphragmatic ultrasound can be used to determine the prevalence of interstitial lung disease involvement in RA as a restrictive disorder. The association between pulmonary function tests (PFTs), potential risk factors, and clinical correlation must be calculated.(8)(9) Anterior chest wall (ACW ) joints undergo joint changes and can be involved along the course of RA yet seems to be underestimated(1) Ultrasonography of ACW can detect those changes even before being clinically evident (10)

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Any patient satisfying 2010 ACR/ EULAR RA classification criteria

Exclusion criteria

* Patients with definite diagnosis for any other systemic autoimmune disorders

Design outcomes

Primary

MeasureTime frameDescription
To determine cardiac and pulmonary involvement in RA patients1 yearBy using spirometry, echocardiography

Secondary

MeasureTime frameDescription
To assess the correlation between cardiopulmonary findings in RA patients with disease activity1 yearUsing DAS28 as a measurement tool for activity
To compare between diaphragmatic ultrasonography and PFT i.e. spirometry as a screening tool for restrictive pulmonary disorders1 yearUsing diaphragmatic ultrasonography and pulmonary function test
To assess correlation between anterior chest wall ultrasound and pulmonary function test in RA patients1 yearAnterior chest wall musculoskeletal ultrasonography

Contacts

Primary ContactYosra Y. Mahmoud
yoyomynmy@gmail.com+201140408392

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026